|
Apr 8
|
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
|
|
Apr 6
|
2 Biotech Stocks to Buy Hand Over Fist in April
|
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
|
Jan 16
|
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
|
|
Jan 15
|
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
|
|
Jan 12
|
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
|
|
Jan 11
|
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
|
|
Jan 11
|
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
|
|
Jan 11
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 11
|
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
|
|
Jan 10
|
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
|
|
Jan 10
|
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
|
|
Jan 10
|
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
|